Eric Karas - Mar 20, 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Mar 20, 2025
Transactions value $
-$125,000
Form type
4
Date filed
3/21/2025, 06:30 PM
Previous filing
Jan 3, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $15K +10K +129.94% $1.50 17.7K Mar 20, 2025 Direct F1
transaction SPRY Common Stock Sale -$140K -10K -56.51% $14.00 7.7K Mar 20, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -10K -1.71% $0.00 575K Mar 20, 2025 Common Stock 10K $1.50 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 2,003 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024.
F2 The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.
F3 Immediately exercisable.